Table 1.
Clinical parameters of patients with AKI and without AKI.
| Parameter | AKI n = 36 | no AKI n = 18 | P-value |
| Reason for lung transplantation | |||
| Emphysema, number/percentage Alpha-1-Antitrypsin deficiency, number/percentage | 12/36 (33%) 1/36 (3%) | 7/18 (39%) 1/18 (6%) | ns, .77 ns, 1.0 |
| Pulmonary fibrosis, number/percentage | 16/36 (44%) | 7/18 (39%) | ns, .78 |
| Cystic fibrosis, number/percentage | 3/36 (8%) | 1/18 (6%) | ns, 1.0 |
| CLAD/re lutx, number/percentage | 2/36 (6%) | 1/18 (6%) | ns, 1.0 |
| Sarcoidosis, number/percentage | 1/36 (3%) | 1/18 (6%) | ns, 1.0 |
| Bronchiectasis, number/percentage | 1/36 (3%) | 0/18 (0%) | ns, 1.0 |
| GvHD, number/percentage | 0/36 (0%) | 1/18 (6%) | ns, .33 |
| Lymphangioleiomyomatosis, number/percentage | 1/36 (3%) | 0/18 (0%) | ns, 1.0 |
| Clinical parameters lung transplant recipients | |||
| Male, number/percentage | 25/36 (69%) | 13/18 (72%) | ns, 1.0 |
| Height, cm | 174 ± 2 | 175 ± 2 | ns, .77 |
| Weight, kg | 70 ± 2 | 68 ± 3 | ns, .68 |
| Age, y | 48 ± 2 | 41 ± 3 | ns, .35 |
| History of smoking, number/percentage | 16/36 (44%) | 9/18 (50%) | ns, .78 |
| Secondary pulmonary hypertension, number/percentage | 15/36 (42%) | 6/18 (33%) | ns, .77 |
| Diabetes mellitus, number/percentage | 4/36 (11%) | 1/18 (6%) | ns, .65 |
| ECMO preoperative, number/percentage | 2/36 (6%) | 0/18 (0%) | ns, .55 |
| Clinical parameters of lung donors | |||
| Male, number/percentage | 24/36 (67%) | 13/18 (72%) | ns, .76 |
| Height, cm | 175 ± 3 | 177 ± 2 | ns, .54 |
| Weight, kg | 83.8 ± 3.1 | 92.0 ± 10.7 | ns, .35 |
| Age, y | 47.3 ± 2.9 | 52.1 ± 3.6 | ns, .32 |
| Duration of ventilation, d | 5.0 ± 0.6 | 4.1 ± 1.0 | ns, .39 |
| Transplantation/ post-transplantation details | |||
| Double lutx, number/percentage | 36/36 (100%) | 18/18 (100%) | ns, 1.0 |
| Minimal invasive lutx, number/percentage | 34/36 (94%) | 16/18 (89%) | ns, .59 |
| Clamshell technique, number/percentage | 2/36 (6%) | 2/18 (11%) | ns, .59 |
| Ischemia time right lung, min | 404 ± 20 | 364 ± 32 | ns, .27 |
| Ischemia time left lung, min | 529 ± 25 | 449 ± 37 | ns, .08 |
| Duration of surgery, h | 5.6 ± 0.5 | 5.0 ± 0.2 | ns, .47 |
| ECMO postoperative | 7/36 (19%) | 4/18 (22%) | ns, 1.0 |
| Duration of ventilation after lutx, h | 12.3 ± 1.8 | 11.9 ± 1.7 | ns, .88 |
| Triple immunosuppressive therapy with tacrolimus, mycophenolate mofetil and prednisolone, number/percentage | 36/36 (100%) | 18/18 (100%) | ns, 1.0 |
| Tacrolimus levels at the day of MRI, μg/L | 10.5 ± 0.7 | 10.1 ± 0.7 | ns, .76 |
All values are given as numbers and percentage or mean ± SEM.
AKI = acute kidney injury, CLAD = chronic lung allograft dysfunction, EC = erythrocyte concentrate, ECMO = extracorporeal membrane oxygenation, FFP = fresh frozen plasma, GvHD = graft-versus-host-disease, lutx = lung transplantation, ns = not significant, re lutx = re lung transplantation, TC = thrombocyte concentrate.